RxDoctor Payments Data

Monica Valenzuela Gamm, DO

Obstetrics & Gynecology · Upland, CANPI 1477575694

Payments from drug & device makers

$1,881in general payments, 2019–2025

Across 84 payments — averaging $22.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$288
  • Revance Therapeutics, Inc.$266
  • Astellas Pharma US Inc$257
  • Duchesnay USA Incorporated$145
  • Mayne Pharma Commercial LLC$93
  • Therapeuticsmd, Inc.$92
  • plus $739 from 18 others

What the payments were for

  • Food & beverage$1,65488%
  • Education$22712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,881 in reported general payments places this provider in the 75th percentile of 3,784 obstetrics & gynecology providers in California.

See all obstetrics & gynecology providers in California

Medicare billing

Part B allowed, 2024
$20,543
Medicare patients
94
Services billed
174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Estradiol203$12,732
Estradiol (Twice Weekly)Estradiol90$8,424
MyrbetriqMirabegron17$8,256
ImvexxyEstradiol22$7,860
Tolterodine Tartrate ErTolterodine Tartrate49$4,249
CombipatchEstradiol/Norethindrone Acet15$3,579
PremproEstrogen,con/M-Progest Acet13$3,161
ProgesteroneProgesterone, Micronized88$2,780
DottiEstradiol31$2,642
YuvafemEstradiol15$1,640
Clobetasol Propionate19$314
Medroxyprogesterone Acetate15$275
ValacyclovirValacyclovir Hcl28$216
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst12$191
Nystatin13$145

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$257$8,25617 claims
Therapeuticsmd, Inc.Imvexxy$92$7,86022 claims
PfizerPrempro$63$3,16113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,784 obstetrics & gynecology providers in California.

Other obstetrics & gynecology in Upland

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →